Business Context and Reporting Period
Company: Galectin Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 22, 2012
Event Date: March 1, 2012 (Filing of Certificate of Change); Effective March 22, 2012 at 4:01 PM EDT.
The Company, incorporated in Nevada, reported the completion of a one-for-six (1:6) reverse stock split of its authorized and issued and outstanding common voting shares.
Key Financial Metrics
This filing is a current report regarding a corporate action and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Reverse Stock Split: The Company effected a 1:6 reverse stock split, reducing the number of outstanding shares and proportionally increasing the share price.
- Registration Statements: The Company has five active registration statements on Form S-8. Pursuant to Rule 416(b), the amount of undistributed shares covered by these statements has been proportionately reduced to reflect the reverse stock split.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard regulatory context of the stock split. The primary purpose of the document is to update the SEC and incorporate the split details by reference into the Company's active Form S-8 registration statements.
Investor Verification Checklist
- Verify the post-split share count and adjusted share price on the Company's stock exchange listing.
- Confirm the updated number of shares available for issuance under the five active Form S-8 registration statements (Nos. 333-109893, 333-116629, 333-159247, 333-176305, and 333-176306).
- Review the Company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.